|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abdelsatir AA, Husain NE, Hassan AT,
Elmadhoun WM, Almobarak AO and Ahmed MH: Potential benefit of
metformin as treatment for colon cancer: The evidence so far. Asian
Pac J Cancer Prev. 16:8053–8058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
5
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varol U, Yildiz I, Salman T, Karabulut B
and Uslu R: Markers to predict the efficacy of bevacizumab in the
treatment of metastatic colorectal cancer. Tumori. 100:370–376.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konda B, Shum H and Rajdev L:
Anti-angiogenic agents in metastatic colorectal cancer. World J
Gastrointest Oncol. 7:71–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen PS, Su JL and Hung MC: Dysregulation
of microRNAs in cancer. J Biomed Sci. 19:902012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: miR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016.PubMed/NCBI
|
|
11
|
Tagscherer KE, Fassl A, Sinkovic T,
Richter J, Schecher S, Macher-Goeppinger S and Roth W: MicroRNA-210
induces apoptosis in colorectal cancer via induction of reactive
oxygen. Cancer Cell Int. 16:422016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui F, Wang S, Lao I, Zhou C, Kong H,
Bayaxi N, Li J, Chen Q, Zhu T and Zhu H: miR-375 inhibits the
invasion and metastasis of colorectal cancer via targeting SP1 and
regulating EMT-associated genes. Oncol Rep. 36:487–493. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:(Database Issue):.
D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong F, Xu T, Shen Y, Zhong S, Chen S,
Ding Q and Shen Z: Dysregulation of miRNAs in bladder cancer:
Altered expression with aberrant biogenesis procedure. Oncotarget.
8:27547–27568. 2017.PubMed/NCBI
|
|
16
|
Zhou L, Xu Z, Ren X, Chen K and Xin S:
MicroRNA-124 (miR-124) inhibits cell proliferation, metastasis and
invasion in colorectal cancer by downregulating Rho-associated
protein kinase 1 (ROCK1). Cell Physiol Biochem. 38:1785–1795. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang H, Ju H, Zhang L, Lu H and Jie K:
microRNA-577 suppresses tumor growth and enhances chemosensitivity
in colorectal cancer. J Biochem Mol Toxicol. 31:e218882017.
View Article : Google Scholar
|
|
18
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lv LY, Wang YZ, Zhang Q, Zang HR and Wang
XJ: miR-539 induces cell cycle arrest in nasopharyngeal carcinoma
by targeting cyclin-dependent kinase 4. Cell Biochem Funct.
33:534–540. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin H and Wang W: MicroRNA-539 suppresses
osteosarcoma cell invasion and migration in vitro and targeting
Matrix metallopeptidase-8. Int J Clin Exp Pathol. 8:8075–8082.
2015.PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:(Database Issue):. D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39:(Database Issue):. D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Griffiths-Jones S, Saini HK, van Dongen S
and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids
Res. 36:(Database Issue):. D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shia J, Klimstra DS, Bagci P, Basturk O
and Adsay NV: TNM staging of colorectal carcinoma: Issues and
caveats. Semin Diagn Pathol. 29:142–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang B, Li Y, Tan F and Xiao Z: Increased
expression of SOX4 is associated with colorectal cancer
progression. Tumour Biol. 37:9131–9137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andersen CL, Christensen LL, Thorsen K,
Schepeler T, Sørensen FB, Verspaget HW, Simon R, Kruhøffer M,
Aaltonen LA, Laurberg S and Ørntoft TF: Dysregulation of the
transcription factors SOX4, CBFB and SMARCC1 correlates with
outcome of colorectal cancer. Br J Cancer. 100:511–523. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guda K, Veigl ML, Varadan V, Nosrati A,
Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, et
al: Novel recurrently mutated genes in African American colon
cancers. Proc Natl Acad Sci USA. 112:1149–1154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vaiopoulos AG, Athanasoula KCh and
Papavassiliou AG: Epigenetic modifications in colorectal cancer:
Molecular insights and therapeutic challenges. Biochim Biophys
Acta. 1842:971–980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bardhan K and Liu K: Epigenetics and
colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar
|
|
35
|
Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z
and Liu Y: MicroRNA-330 is an oncogenic factor in glioblastoma
cells by regulating SH3GL2 gene. PLoS One. 7:e460102012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li G, Yang F, Xu H, Yue Z, Fang X and Liu
J: MicroRNA-708 is downregulated in hepatocellular carcinoma and
suppresses tumor invasion and migration. Biomed Pharmacother.
73:154–159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu H, Zhang Y, Cai XH, Huang JF and Cai L:
Changes in microRNA expression in the MG-63 osteosarcoma cell line
compared with osteoblasts. Oncol Lett. 4:1037–1042. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mirghasemi A, Taheriazam A, Karbasy SH,
Torkaman A, Shakeri M, Yahaghi E and Mokarizadeh A: Down-regulation
of miR-133a and miR-539 are associated with unfavorable prognosis
in patients suffering from osteosarcoma. Cancer Cell Int.
15:862015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gu L and Sun W: miR-539 inhibits thyroid
cancer cell migration and invasion by directly targeting CARMA1.
Biochem Biophys Res Commun. 464:1128–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schepers GE, Teasdale RD and Koopman P:
Twenty pairs of sox: Extent, homology, and nomenclature of the
mouse and human sox transcription factor gene families. Dev Cell.
3:167–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wegner M: From head to toes: The multiple
facets of sox proteins. Nucleic Acids Res. 27:1409–1420. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheung M, Abu-Elmagd M, Clevers H and
Scotting PJ: Roles of Sox4 in central nervous system development.
Brain Res Mol Brain Res. 79:180–191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fang CL, Hseu YC, Lin YF, Hung ST, Tai C,
Uen YH and Lin KY: Clinical and prognostic association of
transcription factor SOX4 in gastric cancer. PLoS One.
7:e528042012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng JH, Jian ZX, Jin HS, Chen SC and
Wang GY: Expression of SOX4 gene and early recurrence of
hepatocellular carcinoma: Their relationship and the clinical
significance. Nan Fang Yi Ke Da Xue Xue Bao. 30:818–819. 2010.(In
Chinese). PubMed/NCBI
|
|
45
|
Wang L, Zhang J, Yang X, Chang YW, Qi M,
Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis
in prostate cancer and promotes epithelial-mesenchymal transition
in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bao ZQ, Zhang CC, Xiao YZ, Zhou JS, Tao YS
and Chai DM: Over-expression of Sox4 and β-catenin is associated
with a less favorable prognosis of osteosarcoma. J Huazhong Univ
Sci Technolog Med Sci. 36:193–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang D, Hao T, Pan Y, Qian X and Zhou D:
Increased expression of SOX4 is a biomarker for malignant status
and poor prognosis in patients with non-small cell lung cancer. Mol
Cell Biochem. 402:75–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
